PMID: 9194110Jun 1, 1997Paper

Safety and immunogenicity of a bivalent Haemophilus influenzae type b/hepatitis B vaccine in healthy infants. Hib-HB Vaccine Study Group

The Pediatric Infectious Disease Journal
D J WestJ C Sadoff

Abstract

To assess the safety, tolerability and immunogenicity of COMVAX, a liquid, bivalent Haemophilus influenzae type b-hepatitis B vaccine, containing the polyribosylribitol phosphate (PRP)-Neisseria meningitidis outer membrane protein complex conjugate used in the Hib vaccine, PedvaxHIB, and the yeast-derived hepatitis B surface antigen (HBsAg) used in the HB vaccine, RECOMBIVAX HB. Eight hundred eighty-two healthy infants, approximately 2 months of age, were enrolled in an open, multicenter (n = 11) clinical trial and randomized to receive either COMVAX (7.5 micrograms of PRP/5 micrograms of HBsAg in 0.5 ml) or concurrent injections of the liquid formulation of PedvaxHIB (P) (7.5 micrograms of PRP in 0.5 ml) and RECOMBIVAX HB (R) (5 micrograms of HBsAg in 0.5 ml) at 2, 4 and 12 or 15 months of age. Safety and tolerability were monitored after each injection. The serum concentrations of anti-PRP and anti-HBs were determined at the time of each vaccination, 2 months after the second vaccination and 1 month after the third vaccination. COMVAX was well-tolerated and proved to be immunologically comparable with a series of concomitant P+R injections. There were no serious adverse experiences attributable to the study vaccines. The most...Continue Reading

References

Oct 1, 1992·The Pediatric Infectious Disease Journal·D J West, H S Margolis
Jun 1, 1990·Pediatric Clinics of North America·D J WestR W Ellis
Jun 1, 1983·The Journal of Infectious Diseases·H KäyhtyP H Mäkelä
Sep 1, 1981·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·W SzmunessA Kellner
Sep 1, 1993·The Journal of Infectious Diseases·D M GranoffT V Murphy
Jan 13, 1993·JAMA : the Journal of the American Medical Association·W G AdamsJ D Wenger

❮ Previous
Next ❯

Citations

Dec 12, 2001·Primary Care·M D Decker
Apr 9, 1999·Vaccine·R W Ellis
Dec 26, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C T Le
Apr 14, 2006·Expert Opinion on Drug Safety·Naor Bar-Zeev, Jim P Buttery
Sep 10, 2004·Pediatric Annals·Gary S Marshall
Apr 13, 2000·Pediatric Clinics of North America·M E Pichichero
Mar 10, 2001·Biologicals : Journal of the International Association of Biological Standardization·L A SwartzJ C May
Apr 26, 2000·Canadian Journal of Microbiology·S MiyazakiK Yamaguchi
Sep 3, 1999·Journal of Biopharmaceutical Statistics·B L Wiens, B Iglewicz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.